San Diego—Once again, a study has found that chimeric antigen receptor (CAR) T cells have impressive activity in highly treatment-experienced patients with a refractory hematologic malignancy. In this Phase II trial, the focus was non-Hodgkin lymphoma (NHL). High rates of activity were achieved with acceptable levels of toxicity at participating institutions, some of which were using CAR T-cell therapy for the first time.
The trial, called ZUMA-1, is “the first reported multicenter